Page last updated: 2024-12-08

acetylstrophanthidin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

acetylstrophanthidin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

acetylstrophanthidin : An acetate ester that is strophanidin acetylated at the 3beta-hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID261075
CHEMBL ID1981679
CHEBI ID59028
SCHEMBL ID3414953
MeSH IDM0045817

Synonyms (43)

Synonym
3beta-acetoxy-5,14-dihydroxy-19-oxo-5beta-card-20(22)-enolide
3beta-acetyloxy-5,14-dihydroxy-19-oxo-5beta-card-20(22)-enolide
3beta,5,14-trihydroxy-19-oxo-5beta-card-20(22)-enolide 3-acetate
CHEBI:59028 ,
acetyl-strophanthidin
NCI60_042066
MEGXP0_001780
3beta,5,14,19-tetrahydroxy-5beta-card-20(22)-enolide 19-acetate
einecs 200-474-0
5beta,14-dihydroxy-19-oxocard-20(22)enolide 3beta-acetate
nsc 92954
5-beta-card-20(22)-enolide, 19-oxo-3-beta,5,14-trihydroxy-, 3-acetate
5beta-card-20(22)-enolide, 3beta,5,14-trihydroxy-19-oxo-, 3-acetate
card-20(22)-enolide, 3-(acetyloxy)-5,14-dihydroxy-19-oxo-, (3beta,5beta)-
NCGC00180716-01
strophanthidin 3-acetate
wln: l e5 b666tj avh e1 iq mq oov1 f- dt5ov ehj
acetylstrophanthidin
strophanthidin, 3-acetate
60-38-8
acetylstrophanthidine
5.beta.-card-20(22)-enolide,5,14-trihydroxy-19-oxo-, 3-acetate
acetyl-k-strophanthidine
acetyltrophanthidin
nsc-92954
nsc92954
erysimupicrone acetate
k-strophanthidin, acetyl-
strophanthidin acetate
ACON1_000278
3-acetyl-strophanthidin
BRD-K48492632-001-01-2
[(3s,5s,8r,9s,10s,13r,14s,17r)-10-formyl-5,14-dihydroxy-13-methyl-17-(5-oxo-2h-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate
3-acetyl strophanthidin
jg33h36364 ,
unii-jg33h36364
CHEMBL1981679
SCHEMBL3414953
AKOS024306999
5.beta.-card-20(22)-enolide, 3.beta.,5,14-trihydroxy-19-oxo-, 3-acetate
Q27126403
DTXSID401018935
strophantidin 3-acetate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" We used Na(+)-sensitive microelectrodes to measure changes in intracellular Na+ activity (aiNa) associated with positive inotropic and toxic effects of acetylstrophanthidin (AS) and a semisynthetic agent, actodigin."( Effects of different cardiac steroids on intracellular sodium, inotropy and toxicity in sheep Purkinje fibers.
Farkas, DE; Norell, MA; Vereault, DV; Wasserstrom, JA, 1991
)
0.48

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves plotted as percentage change from baseline versus concentration of drug were determined for acetylstrophanthidin, isoproterenol, isobutylmethylxanthine, and milrinone."( Decreased inotropic but relatively preserved relaxation response to cyclic adenosine monophosphate-dependent agents in myopathic human myocardium.
Bruce, E; Flemmal, K; Grossman, W; Gutstein, DE; Gwathmey, JK; Markis, JE; Morgan, JP; Ransil, BJ; Travers, KE, 1996
)
0.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID127479Binding affinity against murine monoclonal antibody (mAb)-40-502002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127349Binding affinity against human monoclonal antibody (mAb)-11E62002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID127351Binding affinity against human monoclonal antibody (mAb)-5C22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127352Binding affinity against human monoclonal antibody (mAb)-7F22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127350Binding affinity against human monoclonal antibody (mAb)-1B32002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (117)

TimeframeStudies, This Drug (%)All Drugs %
pre-199084 (71.79)18.7374
1990's24 (20.51)18.2507
2000's8 (6.84)29.6817
2010's1 (0.85)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.07 (24.57)
Research Supply Index4.82 (2.92)
Research Growth Index3.89 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.82%)5.53%
Reviews3 (2.46%)6.00%
Case Studies1 (0.82%)4.05%
Observational0 (0.00%)0.25%
Other117 (95.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]